Generational Equity is pleased to announce a majority acquisition of its client, LGM Pharma, by New Harbor Capital LLC. The transaction closed November 15, 2017.

LGM specializes in streamlining the API supply chain throughout all development stages while providing complete technical capabilities and expert regulatory support for a wide range of products. The company serves many active customers across biotech, generic pharma, contract manufacturing, specialty pharma, CDMOs, academic institutes, compounding and pharmaceutical manufacturing industries, supporting all stages of drug development and commercialization by supplying a wide range of APIs and by providing other value-added services.

Generational Equity Managing Director Julie Sandoval’s team, led by trusted affiliate Mike LoConte with support from Generational Equity VP Rebecca Gruman, successfully closed the deal.

About LGM Pharma

LGM Pharma is an innovation-driven API company, involved in distribution of quality cGMP pharma ingredients to leading pharmaceutical companies. LGM specializes in providing integrated sourcing options, complete technical capabilities and regulatory documentation support for a wide range of APIs.

For more information, visit https://www.lgmpharma.com.

About New Harbor Capital

New Harbor Capital is a Chicago-based private equity firm with over $400 million of capital under management, focused on investing in lower middle-market, growth-oriented healthcare, education and business services companies. Our Partners have been private equity investors for over 20 years, partnering with strong management teams to systematically enable accelerated growth in value creation. Since 2000, the New Harbor team has completed over 200 investments. As an experienced strategic partner, New Harbor supports management with ideas, connections and resources to capitalize on growth potential.

For more information, visit http://www.newharborcapital.com.